SynthesisJournal of cardiovascular electrophysiology2025
Atrial Fibrillation Recurrence Reduction: What Treatments Work Best Postablation? A Network Meta-Analysis.
Synthesis in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating lipid profiles and atrial fibrillation: from incident risk to post-ablation recurrence.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAtrial fibrillation (AF) is the most common cardiac arrhythmia, associated with significant morbidity, including increased risks of stroke, heart failure, and mortality. While catheter ablation is an effective rhythm control strategy, high recurrence rates postprocedure remain a major clinical challenge. Inflammation plays a key role in AF pathogenesis, and anti-inflammatory therapies have emerged as potential adjunctive treatments to reduce recurrence. This study provides the first network meta-analysis evaluating the efficacy of anti-inflammatory therapies in preventing AF recurrence postablation.
methodsA systematic review and network meta-analysis were conducted in accordance with PRISMA-NMA guidelines. Randomized controlled trials examining the effects of colchicine, statins, corticosteroids, ACE inhibitors (ACEIs), and ascorbic acid on AF recurrence postablation were included. Direct and indirect comparisons were synthesized, and treatments were ranked using Surface Under the Cumulative Ranking (SUCRA) values. Risk ratios with 95% confidence intervals were calculated, and evidence quality was assessed using the CINeMA tool.
resultsThe analysis included 13 studies encompassing 21 study arms with 2283 participants. Colchicine and statins demonstrated significant reductions in AF recurrence compared to placebo, with statins achieving the highest SUCRA ranking. Colchicine showed notable efficacy in reducing early recurrence through modulation of inflammatory markers, such as C-reactive protein and interleukin-6. Corticosteroids and ACEIs exhibited nonsignificant effects on recurrence rates, while ascorbic acid demonstrated no benefit. The heterogeneity among included studies was minimal, and sensitivity analyses confirmed the robustness of findings.
conclusionThis study represents the first network meta-analysis evaluating anti-inflammatory therapies for AF recurrence prevention postablation. Colchicine and statins emerged as the most promising treatments, particularly during the early postablation period, highlighting their potential role in reducing inflammation and atrial remodeling. Future research should focus on personalized treatment strategies and long-term evaluation of these therapies to improve patient outcomes and reduce AF burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.